http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 31 Aug 2026 15:13:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Definium+Therapeutics+%28DFTX%29+call+put+ratio+1+call+to+1.9+puts+as+share+price+down+3.6%25/27005073.html <p>Definium Therapeutics (NASDAQ: DFTX) 30-day option implied volatility is at 88; compared to its 52-week of 64 to 156. Call put ratio 1 call to 1.9 puts as share price down 3.6%.</p> http://www.streetinsider.com/Options/Definium+Therapeutics+%28DFTX%29+call+put+ratio+1+call+to+1.9+puts+as+share+price+down+3.6%25/27005073.html Mon, 31 Aug 2026 15:13:37 -0400 DFTX http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Definium+Therapeutics+Inc++%28DFTX%29/27002183.html <p>Stifel analyst Paul Matteis reiterated a Buy rating and $60.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).</p><p>The analyst commented, "We recently hosted a dinner with DFTX CEO Rob Barrow, CMO Dan Karlin and CFO Brandi Roberts to discuss all things DT120. Notable topics included: (1) further appreciation on the strength of the Voyage data in a GAD-specific population, which teases out the robust anxiolytic effect of DT120 as separate from its mood benefits, (2) confidence in the upcoming Panorama data in Sept, where the statistical analysis solely focuses on 100ug vs pbo; the low dose 50ug arm is there http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Definium+Therapeutics+Inc++%28DFTX%29/27002183.html Mon, 31 Aug 2026 09:25:51 -0400 DFTX http://www.streetinsider.com/Analyst+Comments/Stifel+on+Definium+Therapeutics+%28DFTX%29+Post+Mgmt+Dinner+Meet%3A+%27Confident+Overall+in+RegulatoryCommercial+Dynamics%27/27000135.html <p>Stifel on Definium Therapeutics (NASDAQ: DFTX) Post Mgmt Dinner Meet: 'Confident Overall in Regulatory/Commercial Dynamics'.</p><p>The analyst comments "We recently hosted a dinner with DFTX CEO Rob Barrow, CMO Dan Karlin and CFO Brandi Roberts to discuss all things DT120. Notable topics included: (1) further appreciation on the strength of the Voyage data in a GAD-specific population, which teases out the robust anxiolytic effect of DT120 as separate from its mood benefits, (2) confidence in the upcoming Panorama data in Sept, where the statistical analysis solely focuses on 100ug vs pbo; the low dose 50ug arm is there to influence patient http://www.streetinsider.com/Analyst+Comments/Stifel+on+Definium+Therapeutics+%28DFTX%29+Post+Mgmt+Dinner+Meet%3A+%27Confident+Overall+in+RegulatoryCommercial+Dynamics%27/27000135.html Mon, 31 Aug 2026 05:16:51 -0400 DFTX http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: </p><ul class="bwlistdisc"> <li> <b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat</b> <ul class="bwlistcircle"> <li> Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET </li> <li> Moderator: Paul Matteis, Head of Therapeutics Research </li> <li> Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html Wed, 26 Aug 2026 07:01:00 -0400 A.50100012 DFTX O.07579093 O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: </p><ul class="bwlistdisc"> <li> <b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat</b> <ul class="bwlistcircle"> <li> Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET </li> <li> Moderator: Paul Matteis, Head of Therapeutics Research </li> <li> Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html Wed, 26 Aug 2026 07:01:00 -0400 A.50100012 DFTX O.07579093 O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: </p><ul class="bwlistdisc"> <li> <b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat</b> <ul class="bwlistcircle"> <li> Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET </li> <li> Moderator: Paul Matteis, Head of Therapeutics Research </li> <li> Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html Wed, 26 Aug 2026 07:01:00 -0400 A.50100012 DFTX O.07579093 O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: </p><ul class="bwlistdisc"> <li> <b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat</b> <ul class="bwlistcircle"> <li> Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET </li> <li> Moderator: Paul Matteis, Head of Therapeutics Research </li> <li> Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html Wed, 26 Aug 2026 07:01:00 -0400 A.50100012 DFTX O.07579093 O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: </p><ul class="bwlistdisc"> <li> <b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat</b> <ul class="bwlistcircle"> <li> Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET </li> <li> Moderator: Paul Matteis, Head of Therapeutics Research </li> <li> Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html Wed, 26 Aug 2026 07:01:00 -0400 A.50100012 DFTX O.07579093 O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: </p><ul class="bwlistdisc"> <li> <b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat</b> <ul class="bwlistcircle"> <li> Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET </li> <li> Moderator: Paul Matteis, Head of Therapeutics Research </li> <li> Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html Wed, 26 Aug 2026 07:01:00 -0400 A.50100012 DFTX O.07579093 O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: </p><ul class="bwlistdisc"> <li> <b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat</b> <ul class="bwlistcircle"> <li> Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET </li> <li> Moderator: Paul Matteis, Head of Therapeutics Research </li> <li> Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html Wed, 26 Aug 2026 07:01:00 -0400 A.50100012 DFTX O.07579093 O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html <p> NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: </p><ul class="bwlistdisc"> <li> <b>Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat</b> <ul class="bwlistcircle"> <li> Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET </li> <li> Moderator: Paul Matteis, Head of Therapeutics Research </li> <li> Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+to+Participate+at+Upcoming+Investor+Conferences+and+Events/26977205.html Wed, 26 Aug 2026 07:01:00 -0400 A.50100012 DFTX O.07579093 O.12458983 http://www.streetinsider.com/New+Coverage/BofA+Securities+Starts+Definium+Therapeutics+Inc++%28DFTX%29+at+Buy/26938681.html <p>BofA Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Buy rating and a price target of $75.00.</p><p>The analyst comments "We initiate DFTX at Buy with a $75 PO. DFTX is a late-stage clinical biopharmaceutical company developing proprietary forms of psychedelic and empathogenic drugs for brain health disorders. Their lead asset, DT120 (LSD), is in pivotal studies for major depressive disorder (MDD) and generalized anxiety disorder (GAD), with recent best-in-class (BIC) potential demonstrated in the phase 3 studies for both indications. If replicated in ongoing pivotal studies, we think DT120 could be a go-to option http://www.streetinsider.com/New+Coverage/BofA+Securities+Starts+Definium+Therapeutics+Inc++%28DFTX%29+at+Buy/26938681.html Mon, 17 Aug 2026 16:53:43 -0400 DFTX http://www.streetinsider.com/Analyst+Comments/BofA+Securities+Starts+Definium+Therapeutics+Inc++%28DFTX%29+at+Buy/26938681.html <p>BofA Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Buy rating and a price target of $75.00.</p><p>The analyst comments "We initiate DFTX at Buy with a $75 PO. DFTX is a late-stage clinical biopharmaceutical company developing proprietary forms of psychedelic and empathogenic drugs for brain health disorders. Their lead asset, DT120 (LSD), is in pivotal studies for major depressive disorder (MDD) and generalized anxiety disorder (GAD), with recent best-in-class (BIC) potential demonstrated in the phase 3 studies for both indications. If replicated in ongoing pivotal studies, we think DT120 could be a go-to option http://www.streetinsider.com/Analyst+Comments/BofA+Securities+Starts+Definium+Therapeutics+Inc++%28DFTX%29+at+Buy/26938681.html Mon, 17 Aug 2026 16:53:43 -0400 DFTX http://www.streetinsider.com/Hot+Comments/BofA+Securities+Starts+Definium+Therapeutics+Inc++%28DFTX%29+at+Buy/26938681.html <p>BofA Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Buy rating and a price target of $75.00.</p><p>The analyst comments "We initiate DFTX at Buy with a $75 PO. DFTX is a late-stage clinical biopharmaceutical company developing proprietary forms of psychedelic and empathogenic drugs for brain health disorders. Their lead asset, DT120 (LSD), is in pivotal studies for major depressive disorder (MDD) and generalized anxiety disorder (GAD), with recent best-in-class (BIC) potential demonstrated in the phase 3 studies for both indications. If replicated in ongoing pivotal studies, we think DT120 could be a go-to option http://www.streetinsider.com/Hot+Comments/BofA+Securities+Starts+Definium+Therapeutics+Inc++%28DFTX%29+at+Buy/26938681.html Mon, 17 Aug 2026 16:53:43 -0400 DFTX http://www.streetinsider.com/Hot+New+Coverage/BofA+Securities+Starts+Definium+Therapeutics+Inc++%28DFTX%29+at+Buy/26938681.html <p>BofA Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Buy rating and a price target of $75.00.</p><p>The analyst comments "We initiate DFTX at Buy with a $75 PO. DFTX is a late-stage clinical biopharmaceutical company developing proprietary forms of psychedelic and empathogenic drugs for brain health disorders. Their lead asset, DT120 (LSD), is in pivotal studies for major depressive disorder (MDD) and generalized anxiety disorder (GAD), with recent best-in-class (BIC) potential demonstrated in the phase 3 studies for both indications. If replicated in ongoing pivotal studies, we think DT120 could be a go-to option http://www.streetinsider.com/Hot+New+Coverage/BofA+Securities+Starts+Definium+Therapeutics+Inc++%28DFTX%29+at+Buy/26938681.html Mon, 17 Aug 2026 16:53:43 -0400 DFTX http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26937831.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 32,900 common shares of the Company (the "Options") with effective grant dates of August 17, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26937831.html Mon, 17 Aug 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26937831.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 32,900 common shares of the Company (the "Options") with effective grant dates of August 17, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with http://www.streetinsider.com/Press+Releases/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26937831.html Mon, 17 Aug 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26937831.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 32,900 common shares of the Company (the "Options") with effective grant dates of August 17, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26937831.html Mon, 17 Aug 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26937831.html <p> NEW YORK--(BUSINESS WIRE)-- <strong>Definium Therapeutics, Inc.</strong> (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 32,900 common shares of the Company (the "Options") with effective grant dates of August 17, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with http://www.streetinsider.com/Business+Wire/Definium+Therapeutics+Announces+New+Employee+Inducement+Grants/26937831.html Mon, 17 Aug 2026 16:01:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Definium+Therapeutics%2C+++++++++++++++++Filed+by%3A+Commodore+Capital+LP/26930479.html si-local-file:///var/storage/secattach/20260814/26930479.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Definium+Therapeutics%2C+++++++++++++++++Filed+by%3A+Commodore+Capital+LP/26930479.html Fri, 14 Aug 2026 16:13:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Definium+Therapeutics%2C+++++++++++++++++Filed+by%3A+Commodore+Capital+LP/26930479.html si-local-file:///var/storage/secattach/20260814/26930479.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Definium+Therapeutics%2C+++++++++++++++++Filed+by%3A+Commodore+Capital+LP/26930479.html Fri, 14 Aug 2026 16:13:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Analyst+PT+Change/Definium+Therapeutics+Inc++%28DFTX%29+PT+Raised+to+%2455+at+Maxim+Group/26925180.html Maxim Group raised its price target on Definium Therapeutics Inc (NASDAQ: DFTX) to $55.00 (from $50.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Definium+Therapeutics+Inc++%28DFTX%29+PT+Raised+to+%2455+at+Maxim+Group/26925180.html Fri, 14 Aug 2026 08:32:07 -0400 DFTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Definium+Therapeutics%2C+++++++++++++++++Filed+by%3A+DRIEHAUS+CAPITAL+MANAGEMENT+LLC/26924601.html si-local-file:///var/storage/secattach/20260814/26924601.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Definium+Therapeutics%2C+++++++++++++++++Filed+by%3A+DRIEHAUS+CAPITAL+MANAGEMENT+LLC/26924601.html Fri, 14 Aug 2026 07:35:00 -0400 DFTX O.12458983 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Definium+Therapeutics%2C+++++++++++++++++Filed+by%3A+DRIEHAUS+CAPITAL+MANAGEMENT+LLC/26924601.html si-local-file:///var/storage/secattach/20260814/26924601.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Definium+Therapeutics%2C+++++++++++++++++Filed+by%3A+DRIEHAUS+CAPITAL+MANAGEMENT+LLC/26924601.html Fri, 14 Aug 2026 07:35:00 -0400 DFTX O.12458983 http://www.streetinsider.com/Analyst+PT+Change/Definium+Therapeutics+Inc++%28DFTX%29+PT+Raised+to+%2472+at+Wells+Fargo/26917185.html Wells Fargo analyst Benjamin Burnett raised the price target on Definium Therapeutics Inc (NASDAQ: DFTX) to $72.00 (from $68.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Definium+Therapeutics+Inc++%28DFTX%29+PT+Raised+to+%2472+at+Wells+Fargo/26917185.html Thu, 13 Aug 2026 08:42:08 -0400 DFTX